SBIR/STTR Research Award

PATIENT OPTIMIZED BRACHYTHERAPY FOR BREAST CARCINOMA

Award identifier 73bfd9ce79f6c417bb69d7fda22304d1e0ebf4ebaa92cf8aaf36357e9705ae1eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$137,925

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
RADIOMED CORPORATION
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

Breast conserving therapy is by far the preferred choice of the majority of women with early stage breast carcinoma. The recommended options for radiation treatment following lumpectomy are external beam therapy and, in certain cases, an additional local dose by brachytherapy. Avoiding local occurrence is, naturally, the primary goal, but cosmesis and patient comfort are of critical importance. Traditional 192Ir wires and the newer 125I seeds, inserted into the tumor bed are not optimized for breast brachytherapy. These devices are generic products and were not designed with women's health and welfare as the primary objective. This application describes the development of small diameter flexible coiled 103Pd wire source that constrains radiation field to the tumor bed and its margin. The low energy of the source will broaden the indication for use, as it can be used for more superficial tumor beds. It will reduce the need for patient isolation. The extended linear source provides a more homogeneous dose distribution, eliminates hot and cold spots, ameliorates the high contact dose and the possibility of tissue (fat) necrosis. The fine (0.35-mm diameter) profile of the source should improve patient comfort, minimize scar tissue, and improve cosmesis. The effortless source assembly will minimize unintentional exposure to the health care workers. PROPOSED COMMERCIAL APPLICATIONS: The role of brachytherapy for treatment of carcinoma of the breast is evolving. At its height, the number of women receiving breast brachytherapy has been reported to be as high as 26,000 cases/year. A serious impediment for the breast brachytherapy modality has been the absence of an optimal source that delivers a reliable and adequate dose to the intended site but minimizes radiation complications to adjacent organs and attending healthcare workers. The source described in this application is believed to address many of these concerns and create major opportunity for brachytherapy of the breast and other organs.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.